Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EXEL message board posts where the ticker symbol EXEL has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EXEL SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000123 Size: 10 KB
2018-07-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000121 Size: 11 KB
2018-06-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000117 Size: 6 KB
2018-06-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000116 Size: 12 KB
2018-06-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000115 Size: 10 KB
2018-06-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000111 Size: 7 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000110 Size: 9 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000109 Size: 7 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000108 Size: 7 KB
2018-05-24
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000107 Size: 7 KB
2018-05-24
More EXEL SEC Filings


Related news from
Mon, 16 Jul 2018
12:06:23 +0000
See what the IHS Markit Score report has to say about Exelixis Inc.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.
Wed, 11 Jul 2018
23:05:00 +0000
Top 5 Biotech Stocks for 2018
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
Mon, 09 Jul 2018
18:49:29 +0000
Why Analysts are Mostly Positive On Acceleron Pharma
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
Thu, 05 Jul 2018
19:23:33 +0000
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10. On June 26, Exelixis stock rose ~8.0% to close at $21.03 from its previous day’s close of $19.54 on June 25. 
Wed, 04 Jul 2018
21:00:00 +0000
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
– Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma –
Tue, 03 Jul 2018
16:10:30 +0000
Understanding Exelixis’s Valuations and Cash Flow Trend
In the first quarter of 2018, Exelixis (EXEL) generated $71.8 million from operating activities compared to $68.85 million in Q1 2017. The increase in operating cash flow was primarily attributable to the increase in Exelixis’s net income, offset by an increase in trade and other receivables of $10.75 million in Q1 2018 compared to a decrease of $6.54 million in Q1 2017. It was also attributable to unbilled collaboration revenue of $38 million in Q1 2018 and a decrease in deferred revenues of $2.65 million compared to an increase of $35.14 million in Q1 2017.
Tue, 03 Jul 2018
16:10:29 +0000
Taking Stock of Exelixis’s Operational Performance
Exelixis (EXEL) has collaboration agreements with Ipsen, Takeda, and Genentech. Revenues from Ipsen increased from $4.5 million in Q1 2017 to $53.81 million in Q1 2018. Under Exelixis’s collaboration with Takeda for cabozantinib, revenues were $2.92 million in Q1 2018 compared to $2.68 million in Q1 2017. Revenues from Genentech on the US commercialization of Cotellic were $1.34 million in Q1 2018 compared to $2.29 million in Q1 2017.
Tue, 03 Jul 2018
16:10:29 +0000
Analyzing Exelixis’s Revenue Trend
Exelixis (EXEL) generated total revenues of $212.34 million in Q1 2018 compared to $80.88 million in Q1 2017. It generates revenues from product sales and collaborations. Exelixis’s collaboration revenues also registered strong growth in the quarter, rising from $12 million in Q1 2017 to $78 million in Q1 2018.
Tue, 03 Jul 2018
16:10:28 +0000
How Much Upside Do Analysts See in Exelixis Stock?
Exelixis (EXEL) is a biotechnology company focused on discovering, developing, and commercializing drugs to treat cancer. Two of them—Cabometyx and Cometriq—are derived from cabozantinib, a multiple tyrosine kinase inhibitor. Exelixis’s third commercial product, Cotellic, is a MEK inhibitor approved as part of a combination therapy for advanced melanoma and is marketed in collaboration with Genentech.
Thu, 28 Jun 2018
12:51:00 +0000
3 Top Healthcare Stocks to Buy Right Now
A cancer-drug developer, generic-drug manufacturer, and medical device kingpin may be just what the doctor ordered.
Wed, 27 Jun 2018
12:42:12 +0000
Exelixis (EXEL) Jumps: Stock Rises 8%
Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Wed, 27 Jun 2018
12:00:00 +0000
Exelixis to Be Added to the S&P MidCap 400 Index
Exelixis, Inc. (EXEL) today announced that it will be added to Standard & Poor’s (S&P) MidCap 400 index, effective prior to the open of trading on Monday, July 2. The company will be classified under S&P’s Global Industry Classification Standard (GICS) Biotechnology Sub-Industry index. “S&P is a highly respected organization in the investment and financial communities, so Exelixis’ addition to the S&P MidCap 400 is an important milestone as we continue on our growth trajectory,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.
Tue, 26 Jun 2018
12:34:34 +0000
Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...
Tue, 26 Jun 2018
12:05:00 +0000
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
Which of these cancer-focused biotech stocks is the better pick right now?
Tue, 26 Jun 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Exelixis and Zafgen
NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...
Mon, 25 Jun 2018
22:23:00 +0000
Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400; Clarifications to S&P U.S. Indices Methodology
NEW YORK, June 25, 2018 /PRNewswire/ -- S&P MidCap 400 constituent Copart Inc. (CPRT) will replace Dr Pepper Snapple Group Inc. (DPS) in the S&P 500, and Exelixis Inc. (EXEL) will replace Copart in the S&P MidCap 400 effective prior to the open of trading on Monday, July 2. Dr Pepper Snapple Group, which is merging with privately held Keurig Green Mountain Inc., is changing its name to Keurig Dr Pepper Inc. and its ticker symbol (NYSE:KDP) in a transaction expected to be completed soon. The newly combined company will no longer be eligible for inclusion in the S&P 500 as its Investable Weight Factor (IWF), which measures the percentage of free float available to the public, is expected to fall well below the 50% eligibility threshold needed for continued inclusion in the index.
Thu, 21 Jun 2018
12:25:00 +0000
Today's Research Reports on Trending Tickers: bluebird bio and Exelixis
NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...
Thu, 21 Jun 2018
11:30:35 +0000
Exelixis Inc (NASDAQ:EXEL) Has Attractive Fundamentals, Here’s Why
Attractive stocks have exceptional fundamentals. In the case of Exelixis Inc (NASDAQ:EXEL), there’s is a financially-healthy company with a great history and an optimistic growth outlook. Below is a briefRead More...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I joined almost three years ago and have never been sorry. The search features here are terrific." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards